Galectin Therapeutics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $365.1M
- Price
- $3.62
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.72%
- Volume
- 176.0K
About
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
Quick stats
Shares outstanding100.8M
Computed float43.7M
Float / shares43.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001133416
AI Summary
AI-generated1/11
minorneutralother
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Galectin Therapeutics announced that management will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14, 2026 at 11:30 AM ET, with one-on-one meetings available during the September 14-16 event.
The company's lead drug belapectin, which holds FDA Fast Track designation, is in development for MASH cirrhosis with portal hypertension, while additional oncology programs are dependent on finding a suitable partner.
This is a routine investor-relations announcement with no new clinical, financial, or regulatory disclosure; a webcast will be available live and archived on the company's investor site.